NCT00527514CompletedPhase 3
A Prospective, Open-label Study to Assess the Efficacy and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Subjects With Stage 1 and Stage 2 Hypertension
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Daiichi Sankyo
- Enrollment
- 185
- Primary Endpoint
- Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring
Study Overview
Brief Summary
This study will be conducted to assess the efficacy and safety of an amlodipine/olmesartan treatment regimen in stage 1 and stage 2 hypertensive subjects.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Males or females greater than or equal to 18 years of age
- •Patients with a mean seated systolic blood pressure (MSSBP) greater than or equal to 140 mm Hg but less than or equal to 199 mm Hg or a mean seated diastolic blood pressure (MSDBP) greater than or equal to 90 mm Hg and less than or equal to 109 mm Hg, following a period of taking only placebo
- •Patients with a mean daytime (8AM-4PM) systolic blood pressure greater than or equal to 135 mm Hg and less than or equal to 199 mm Hg and a mean daytime diastolic blood pressure less than or equal to 109 mm Hg as measured by an ambulatory blood pressure monitoring device (ABPM), after a period of taking only placebo
- •If female, must have negative serum pregnancy test at screening and be either post-menopausal (greater than or equal to 1 year), had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study
Exclusion Criteria
- •History of stroke or transient ischemic attack (TIA) within the last one year
- •History of myocardial infarction, coronary angioplasty, coronary artery bypass graft, or heart failure within the past 6 months
- •Patients with secondary hypertension of any etiology, such as renal disease, pheochromocytoma, or Cushing's syndrome
- •Type I diabetes. Patients with Type II diabetes on stable treatment, with fasting glucose <160 mg/dl may enroll
- •Patients with hemodynamically significant cardiac valvular disease
- •Patients with clinically significant cardiac conduction defects, including second or third degree AV block, left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication
Arms & Interventions
1
Experimental
Intervention: Amlodipine (Drug)
1
Experimental
Intervention: Olmesartan medoxomil plus amlodipine (Drug)
Outcomes
Primary Outcomes
Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring
Time Frame: Baseline to 12 Weeks
Secondary Outcomes
- Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg Group.(Baseline to end of week 3)
- Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 20 mg Group.(Baseline to end of week 6)
- Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 40 mg Group(Baseline to end of week 9)
- Change From Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure(Baseline to 12 weeks)
- Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 10 mg + Olmesartan 40 mg Group(Baseline to end end of week 12)
Investigators
Similar Trials
Completed
Phase 3
Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled HypertensionHypertensionNCT00523744Novartis257
Terminated
Not Applicable
Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino PatientsHypertensionNCT01200407Pfizer615
Active, not recruiting
Phase 4
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsMetastatic Castration-resistant Prostate CancerNCT05457257AstraZeneca43
Completed
Phase 4
An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian FederationModerate to Severe Plaque PsoriasisNCT01644396AbbVie (prior sponsor, Abbott)50
Completed
Phase 3
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular HypertrophyHypertrophy, Left Ventricular HypertensionNCT00446563Novartis90